Iovance Biotherapeutics, Inc.

IOVA · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$372,177-$444,037-$395,893-$342,252
Dep. & Amort.$43,606$33,127$21,135$13,980
Deferred Tax-$2,828-$3,479$0$0
Stock-Based Comp.$109,627$62,625$84,022$69,765
Change in WC-$122,556-$6,521-$2,892$24,553
Other Non-Cash-$8,649-$3,535$871$6,013
Operating Cash Flow-$352,977-$361,820-$292,757-$227,941
Investing Activities
PP&E Inv.-$11,069-$22,290-$20,425-$37,574
Net Acquisitions-$52,573-$212,633-$276,880-$37,706
Inv. Purchases-$460,769-$205,902-$245,816-$725,208
Inv. Sales/Matur.$428,000$285,583$522,696$762,914
Other Inv. Act.$0$0$276,880$37,706
Investing Cash Flow-$96,411-$155,242$256,455$132
Financing Activities
Debt Repay.$0$0$0$1,000
Stock Issued$397,304$463,281$189,502$203,156
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.-$6,640-$322$648$35,112
Financing Cash Flow$390,664$462,959$190,150$239,268
Forex Effect-$541-$2,740$0$0
Net Chg. in Cash-$59,265-$56,843$153,848$11,459
Supplemental Information
Beg. Cash$181,318$238,161$84,313$72,854
End Cash$122,053$181,318$238,161$84,313
Free Cash Flow-$364,046-$384,110-$313,182-$265,515